The Truth About Compounded Semaglutide and Salt Forms

The two-word problem on the label: "sodium" and "acetate"

If you have shopped for semaglutide outside the brand-name products Ozempic and Wegovy, you have probably seen vials and order pages that say "semaglutide sodium" or "semaglutide acetate." Those extra words are not a formality. They describe salt forms of the molecule, and the U.S. Food and Drug Administration has flagged them as a documented red flag.

The FDA's position is blunt: the salt forms semaglutide sodium and semaglutide acetate are different active ingredients than the semaglutide base used in the approved drugs. The agency has stated it is not aware of any basis for compounding using these salt forms that would meet the requirements of the Federal Food, Drug, and Cosmetic Act, and that products containing these salts have not been shown to be safe and effective. In plain terms: the FDA considers a salt-form product to be something other than the medicine that was actually tested in clinical trials and approved.

This is the single most useful thing a consumer can learn from this topic. The approved drug substance is semaglutide (the base). When a label adds "sodium" or "acetate," the FDA treats it as a different substance whose safety, potency, and behavior in the body have not been established — not a generic, not an equivalent, and not something the agency has reviewed.

Why "compounded" does not mean "FDA-approved"

Compounding is a legitimate, long-standing pharmacy practice: a licensed pharmacist or outsourcing facility combines or alters ingredients to make a medication tailored to a patient — for example, a different form for someone with an allergy to a dye or filler. Crucially, compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before they reach patients the way it reviews a brand-name or generic drug.

That distinction is easy to lose in marketing copy. A telehealth site advertising "compounded semaglutide" at a fraction of the brand price can read like a cheaper version of the same approved product. It is not. The molecule may be the same in some cases, but the regulatory guarantees that come with an approved drug — verified manufacturing, characterized impurities, a known potency, a reviewed label — are absent by definition. With a compounded product you are relying entirely on the practices of the specific pharmacy or facility that made it, plus whatever oversight the relevant state board provides.

This is why the salt-form issue matters so much. With an approved drug, the active ingredient is fixed and verified. With a compounded product, the identity of the active ingredient itself depends on what the compounder sourced — and the FDA has explicitly warned that some of what is being sourced and sold as "semaglutide" is a salt form it does not consider lawful to compound.

503A vs. 503B: the two kinds of compounding, briefly

U.S. compounding falls into two statutory buckets, and the difference shapes everything downstream. Section 503A pharmacies are traditional compounding pharmacies that make patient-specific preparations, typically against an individual prescription, and are regulated primarily by state boards of pharmacy. Section 503B outsourcing facilities register with the FDA, are subject to federal current good manufacturing practice (CGMP) standards, and can produce larger batches without a patient-specific prescription.

503B facilities face meaningfully more federal oversight, but neither category produces an FDA-approved drug. Both make products that bypass premarket review. The reason large volumes of compounded semaglutide flooded the market at all traces back to a specific legal mechanism: drug shortages. When a drug is on the FDA's shortage list, compounders are given more latitude to make copies of it to fill the gap. That is the context that created the compounded-GLP-1 boom — and, as covered below, it is the context that is now closing.

The shortage window opened the door — and then it closed

Demand for semaglutide outran supply, and the FDA placed semaglutide on its drug shortage list. Under that status, 503A pharmacies and 503B facilities were permitted, with conditions, to compound semaglutide products — which is how a prescription-only, patent-protected drug came to be sold widely in compounded form.

That window is no longer open. The FDA determined the shortage was resolved and removed semaglutide from the shortage list, with the update reflected in February 2025. The agency then set staggered wind-down deadlines for enforcement discretion: roughly late April 2025 for 503A pharmacies and late May 2025 for 503B outsourcing facilities, dates that were further shaped by litigation in which a federal court declined to block the FDA. Industry analysts have described the FDA as moving to permanently close the door on large-scale compounding of GLP-1 drugs.

For a reader trying to make sense of the market, the takeaway is this: the legal justification that made mass-market compounded semaglutide possible has largely expired. Products still being sold after these deadlines occupy a much grayer zone than they did during the shortage, and "there was a shortage" is no longer a current explanation for why a compounded copy is on the market.

What the lab data actually shows — and what it does not

It is tempting to assume every compounded vial is contaminated junk, but the honest picture is more specific. Two strands of evidence are worth separating.

First, peer-reviewed analytical work has documented that follow-on (non-originator) semaglutide drug substances and products can differ from the brand originator. A 2024 study in Pharmaceutical Research (Hach et al.) reported that, compared with originator products, follow-on injectable semaglutide drug substances and products carried new impurities and impurity patterns — including high-molecular-weight proteins, trace metals, counterions, and residual solvents. That is a quality-and-characterization finding: the input material is not necessarily identical to what goes into the approved drug.

Second, and importantly distinct, a 2024 study in the Journal of Medical Internet Research (Ashraf et al.) bought semaglutide from online sellers operating without a prescription and found severely compromised products — measured purity ranging from about 7.7% to 14.4% against label claims near 99%, semaglutide content exceeding labeled amounts, and endotoxin detected in all samples. The crucial caveat: those products came from illicit, prescription-free online sellers, not from licensed U.S. compounding pharmacies. It is not evidence about every compounder, but it is a stark illustration of what unregulated "semaglutide" can contain — and salt-form products often travel through exactly these gray-market channels.

The defensible synthesis: compounded and follow-on semaglutide is not automatically the same molecule at the same quality as the approved drug, the FDA has not verified it, and the worst of the market (often prescription-free, often salt-form) can be wildly off-label in purity and content.

Dosing errors: a separate, well-documented hazard

Beyond what is in the vial, there is the problem of how compounded injectable semaglutide gets used. In 2024 the FDA issued an alert about dosing errors with compounded injectable semaglutide products, reporting adverse events — some requiring hospitalization — that may be tied to overdoses.

The mechanism is mundane and exactly why approved products use prefilled, dose-metered pens. Patients drawing medication from a vial into a syringe, often without injection experience and faced with unfamiliar units of measurement, made measurement errors. The FDA noted instances of patients administering doses five to ten times greater than intended, with reported effects including severe nausea and vomiting, dehydration, and other GLP-1 overdose symptoms. This is a delivery-format risk layered on top of the ingredient-identity and quality risks already discussed — and it is one of the most concrete, documented harms in the entire compounded-GLP-1 story.

None of this is dosing guidance; the point is structural. Vials plus self-measurement plus inexperience is a known recipe for overdose, independent of whatever else is or isn't wrong with the product.

A practical red-flag checklist

You do not need to be a chemist to apply what the regulators and analysts have established. A few honest filters:

Read the active ingredient line. If it says semaglutide sodium or semaglutide acetate, treat it as the FDA does — as a salt form the agency does not consider an approved active ingredient, not a bargain version of Ozempic or Wegovy. "Base" semaglutide is the approved substance; the salt qualifier is the tell.

Distrust prescription-free sellers entirely. The worst lab results in the literature come from products bought online without a prescription. Research-use-only powders, "not for human consumption" disclaimers paired with injection instructions, and no licensed prescriber in the loop are markers of the unregulated tier, not the compounding-pharmacy tier.

Remember the calendar. The drug-shortage justification that made compounded semaglutide broadly available has largely lapsed as of 2025. A site still selling it as if nothing changed is a reason for more scrutiny, not less.

Know what you are giving up. Even a reputable compounder is not selling you an FDA-approved drug. There is no premarket review of that specific product's safety, potency, or quality. For some people and some situations a compounded preparation is legitimately appropriate — but it should be a clear-eyed decision made with a licensed prescriber who knows the source, not a default driven by price alone.